Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence of Yersinia Species in the Ileum of Crohn's Disease Patients and Controls.
Le Baut G, O'Brien C, Pavli P, Roy M, Seksik P, Tréton X, Nancey S, Barnich N, Bezault M, Auzolle C, Cazals-Hatem D, Viala J, Allez M; REMIND GROUP; Hugot JP, Dumay A. Le Baut G, et al. Among authors: seksik p. Front Cell Infect Microbiol. 2018 Sep 21;8:336. doi: 10.3389/fcimb.2018.00336. eCollection 2018. Front Cell Infect Microbiol. 2018. PMID: 30298122 Free PMC article.
Patchy distribution of mucosal lesions in ileal Crohn's disease is not linked to differences in the dominant mucosa-associated bacteria: a study using fluorescence in situ hybridization and temporal temperature gradient gel electrophoresis.
Vasquez N, Mangin I, Lepage P, Seksik P, Duong JP, Blum S, Schiffrin E, Suau A, Allez M, Vernier G, Tréton X, Doré J, Marteau P, Pochart P. Vasquez N, et al. Among authors: seksik p. Inflamm Bowel Dis. 2007 Jun;13(6):684-92. doi: 10.1002/ibd.20084. Inflamm Bowel Dis. 2007. PMID: 17206669 Clinical Trial.
A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease.
Abitbol V, Briot K, Roux C, Roy C, Seksik P, Charachon A, Bouhnik Y, Coffin B, Allez M, Lamarque D, Chaussade S. Abitbol V, et al. Among authors: seksik p. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1184-9. doi: 10.1016/j.cgh.2007.05.016. Epub 2007 Aug 1. Clin Gastroenterol Hepatol. 2007. PMID: 17683996 Clinical Trial.
Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease.
Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, Brixi H, Gornet JM, Altwegg R, Beau P, Duclos B, Bourreille A, Faivre J, Peyrin-Biroulet L, Fléjou JF, Carrat F; CESAME Study Group. Beaugerie L, et al. Among authors: seksik p. Gastroenterology. 2013 Jul;145(1):166-175.e8. doi: 10.1053/j.gastro.2013.03.044. Epub 2013 Mar 27. Gastroenterology. 2013. PMID: 23541909
Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease.
Rajca S, Grondin V, Louis E, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Paintaud G, Piver E, Allez M, Mary JY, Sokol H, Colombel JF, Seksik P. Rajca S, et al. Among authors: seksik p. Inflamm Bowel Dis. 2014 Jun;20(6):978-86. doi: 10.1097/MIB.0000000000000036. Inflamm Bowel Dis. 2014. PMID: 24788220 Clinical Trial.
237 results